Page 27 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Erytech Pharma S.A.March 4, 2021 GMT ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Lyon (France) and Cambridge, MA (U.S.), March 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth qua...

Nicox Announces 2020 Financial Results and 2021 Key Milestones Nachrichtenquelle: globenewswire  |  01.03.2021, 07:30  |  127  Net revenue Cash position increased to €47.2 million as of December 31, 2020March 1 st, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the financial and operating results for Nicox and its subsidiaries (the “Nicox Group”) for the year ended December 31, 2020, as approved by...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified, consistent...

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021 January 29, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period of interest-only payments on the outstanding principal starting on February 1, 2021, and an extension of the overall period of the loan by 6 months to July 2024. The new one-year interest-only period is expected to provide appr...